

ClotChip: A Microfluidic Dielectric Sensor for Point-of-Care Assessment of Hemostasis

Debnath Maji, *Student Member, IEEE*, Michael A. Suster, *Member, IEEE*, Erdem Kucukal, Ujjal D. S. Sekhon, Anirban Sen Gupta, Umut A. Gurkan, *Member, IEEE*, Evi X. Stavrou, and Pedram Mohseni [✉], *Senior Member, IEEE*

Abstract—This paper describes the design, fabrication, and testing of a microfluidic sensor for dielectric spectroscopy of human whole blood during coagulation. The sensor, termed ClotChip, employs a three-dimensional, parallel-plate, capacitive sensing structure with a floating electrode integrated into a microfluidic channel. Interfaced with an impedance analyzer, the ClotChip measures the complex relative dielectric permittivity, ϵ_r , of human whole blood in the frequency range of 40 Hz to 100 MHz. The temporal variation in the real part of the blood dielectric permittivity at 1 MHz features a time to reach a permittivity peak, T_{peak} , as well as a maximum change in permittivity after the peak, $\Delta\epsilon_{r,\text{max}}$, as two distinct parameters of ClotChip readout. The ClotChip performance was benchmarked against rotational thromboelastometry (ROTEM) to evaluate the clinical utility of its readout parameters in capturing the clotting dynamics arising from coagulation factors and platelet activity. T_{peak} exhibited a very strong positive correlation ($r = 0.99$, $p < 0.0001$) with the ROTEM clotting time parameter, whereas $\Delta\epsilon_{r,\text{max}}$ exhibited a strong positive correlation ($r = 0.85$, $p < 0.001$) with the ROTEM maximum clot firmness parameter. This paper demonstrates the ClotChip potential as a point-of-care platform to assess the complete hemostatic process using $< 10 \mu\text{L}$ of human whole blood.

Index Terms—Blood coagulation, capacitive sensor, dielectric coagulometry, dielectric spectroscopy, hemostasis, microfluidics, permittivity, point-of-care diagnostics, whole blood.

Manuscript received April 28, 2017; revised July 27, 2017; accepted August 8, 2017. Date of publication September 12, 2017; date of current version December 29, 2017. This work was supported in part by the Case-Coulter Translational Research Partnership, the Advanced Platform Technology Center—a VA Research Center of Excellence—at the Case Western Reserve University, and NIH Grant 5R01 HL121212. This paper was recommended by Associate Editor M. Bucolo. (*Corresponding author: Pedram Mohseni.*)

D. Maji, M. A. Suster, and P. Mohseni are with the Department of Electrical Engineering and Computer Science, Case Western Reserve University, Cleveland, OH 44106 USA (e-mail: debnath.maji@case.edu; mas20@case.edu; pedram.mohseni@case.edu).

E. Kucukal and U. A. Gurkan are with the Department of Mechanical and Aerospace Engineering, Case Western Reserve University, Cleveland, OH 44106 USA (e-mail: exk238@case.edu; uxg23@case.edu).

U. D. S. Sekhon and A. S. Gupta are with the Department of Biomedical Engineering, Case Western Reserve University, Cleveland, OH 44106 USA (e-mail: uxs39@case.edu; axs262@case.edu).

E. X. Stavrou is with the Department of Medicine, Hematology and Oncology Division, Case Western Reserve University School of Medicine, Cleveland, OH 44106 USA, and also with the Department of Medicine, Louis Stokes Cleveland Department of Veterans Affairs Medical Center, Cleveland, OH 44106 USA (e-mail: exs300@case.edu).

Color versions of one or more of the figures in this paper are available online at <http://ieeexplore.ieee.org>.

Digital Object Identifier 10.1109/TBCAS.2017.2739724

I. INTRODUCTION

TIMELY characterization of the coagulation system and platelet function is a critical component of caring for patients who are severely injured (and hemorrhaging), undergoing surgery, or receiving antiplatelet/anticoagulant therapies. In these scenarios, physicians must make time-critical decisions on therapeutic management and transfusion practices, or to maintain safe anticoagulant levels [1]. Currently available conventional coagulation tests include the activated partial thromboplastin time (aPTT), prothrombin time (PT), and international normalized ratio (INR). These *in-hospital* tests are performed on blood plasma and require a central laboratory with trained personnel. However, access to specialized coagulation testing in a central laboratory is often limited in community hospitals as well as at point-of-injury in remote battlefield or civilian conditions, and the long delay associated with such tests means that results are obtained at time points much later than the onset of hemostatic imbalance.

On the other hand, several handheld, point-of-care (POC) coagulation devices are currently commercially available [2]. However, POC INR devices exhibit variable performance and are primarily limited to monitoring patients on warfarin anticoagulant therapy, while other devices have low thromboplastin and partial thromboplastin reagent sensitivity (e.g., i-STAT), resulting in only a crude snapshot of the coagulation process. Furthermore, no existing handheld, portable device can provide concurrent information on platelet function. Thromboelastography (TEG) and rotational thromboelastometry (ROTEM) are two viscoelastic whole blood assays that allow for the analysis of several aspects of clot formation and strength, representing a global measure of hemostasis. In fact, TEG and ROTEM can be used at the patient bedside, and are increasingly being utilized in the diagnosis and treatment of patients at high risk of bleeding, such as those undergoing cardiac surgery or suffering from trauma [3]–[6]. However, TEG and ROTEM are not easily miniaturized due to the presence of moving parts and require highly trained technical personnel. Additionally, their results are operator-dependent and prone to processing/sampling errors, and the mechanical force introduced by these assays can interfere with the natural coagulation process.

Recently, several microfabricated sensors have been developed for POC blood coagulation monitoring. Blood viscosity during coagulation can be measured by monitoring a frequency shift when the blood sample is in direct contact with a

microfabricated resonant structure such as a magnetoelastic transducer [7], piezoelectric quartz crystal [8], thin-film bulk acoustic resonator [9], or microfabricated cantilever beam [10], [11]. In other devices, blood viscosity as well as platelet retraction forces are measured by using optical methods to monitor the deflection of microfabricated pillars in contact with blood during the coagulation process [12], [13]. Nonetheless, the force applied when blood is in direct contact with a mechanical transducer can potentially interfere with the natural coagulation process. Non-contact methods have also been developed; but they require the use of discrete ultrasonic transducers [14] or laser illumination and optical microscopy [15], and need a blood sample volume of 100 μL to 1 mL.

In contrast, dielectric spectroscopy (DS) is a fully electrical, label-free, and nondestructive measurement technique that can enable a simple and easy-to-use POC device for extracting information on the physiologic properties of blood in real time. DS is the quantitative measurement of the complex relative dielectric permittivity, ϵ_r , of a material-under-test (MUT) versus frequency, and is a well-established method to study the molecular and cellular composition of a variety of biomaterials [16], [17]. The main DS response of blood in the MHz-frequency range is characterized as a dispersion region that arises from the interfacial polarization of cellular components [18], [19]. In fact, DS in the MHz-range has been previously used to determine the properties of blood cellular components [20], [21] and, in particular, is shown to be sensitive to red blood cell (RBC) aggregation and deformation [22]–[24], two critical processes involved in blood coagulation [25]. DS to assess the blood coagulation process is termed *dielectric coagulometry*, and while early work on dielectric coagulometry revealed sensitivity to both clotting time and platelet activity [26]–[28], this technique has been restricted to studies using laboratory-based benchtop measurement equipment and $>100 \mu\text{L}$ -volume samples [29]–[31].

In this paper, we present a novel microsensors, termed ClotChip, to perform dielectric coagulometry measurements in a low-cost and disposable microfluidic channel using $<10 \mu\text{L}$ of whole blood. We have expanded our previous work [32], [33] by performing controlled experiments with healthy human whole blood samples that are modified *in vitro* with various activators and inhibitors of the coagulation process. We then examine the ClotChip readout, defined as the normalized real part of the blood permittivity at 1 MHz, and evaluate two distinct parameters of the ClotChip readout that are sensitive to two different aspects of the coagulation process. Specifically, the time to reach a peak in permittivity is shown to be sensitive to coagulation time (i.e., time for a fibrin clot to form), and the maximum change in permittivity after the peak is shown to be sensitive to platelet activity. This is accomplished by demonstrating a strong positive correlation between the ClotChip readout parameters and clinically relevant diagnostic parameters of ROTEM.

A dielectric microsensors that can extract distinct information pertaining to abnormalities of the coagulation process, arising from coagulation factors or platelet activity, from a single drop of whole blood paves the way for developing a handheld instrument, as conceptually illustrated in Fig. 1, to rapidly provide



Fig. 1. Conceptual illustration of a POC dielectric coagulometer utilizing the proposed ClotChip microfluidic sensor.

a comprehensive diagnostic profile of hemostatic defects at the POC.

The paper is organized as follows. Section II describes the analysis, design, and fabrication of the ClotChip sensor along with the experimental methods. Section III presents our results from controlled experiments with healthy human whole blood samples, showcasing the ClotChip utility in assessing the blood coagulation time and platelet activity. Finally, Section IV draws some conclusions from this work.

II. SENSOR DESIGN AND METHODS

A. ClotChip Design and Analysis

A novel, microfluidic, dielectric sensor with a parallel-plate capacitive sensing structure has been developed, as illustrated in Fig. 2(A). A microfluidic channel separates a pair of planar sensing electrodes from a floating electrode to form two three-dimensional (3D) capacitive sensing areas that are connected in series through the floating electrode. As the MUT passes through this capacitive sensing area, the sensor impedance changes based on the dielectric permittivity of the MUT. At the measurement frequency, ω , the complex impedance, Z_S , of the capacitive sensing area can be expressed as [34]:

$$Z_S = \frac{1}{j\omega C_0(\epsilon'_r - j\epsilon''_r)}, \quad (1)$$




Fig. 2. Illustration of the ClotChip design and fabrication steps along with the experimental setup. (A) Cross-sectional and top views of the ClotChip. (B) ClotChip fabrication and assembly procedure. (C) Photograph of the fabricated ClotChip loaded with human whole blood as the MUT. (D) Photograph of the testing setup.

where C_0 is the nominal, series-connected, air-gap capacitance of the parallel-plate capacitive sensing area. ϵ'_r and ϵ''_r are the real and imaginary parts, respectively, of ϵ_r of the MUT and can be calculated from the measurements of Z_S using:

$$\epsilon'_r = \frac{\text{imag}(Z_S^{-1})}{\omega C_0}, \quad (2)$$

and

$$\epsilon''_r = \frac{\text{real}(Z_S^{-1})}{\omega C_0}. \quad (3)$$

The permittivity of human whole blood in a microfluidic dielectric sensor exhibits several distinct frequency-dependent regions. For frequencies below a few hundreds of kHz, ϵ'_r is dominated by the impedance of the capacitive double-layer (CDL) that forms at the electrode-solution interface and is primarily due to the blood ionic content. The CDL is also known to be influenced by other factors, including the electrode geometry and material, surface roughness, and temperature, which

are unrelated to the biological properties of blood, and might exhibit a time-dependent drift. Therefore, measurements within a CDL-dominated frequency range may be affected by factors not related to the blood coagulation process. On the other hand, ϵ'_r exhibits a characteristic dispersion region from a few hundreds of kHz to a few tens of MHz that arises from the interfacial polarization between the suspended RBCs and the surrounding conducting medium (plasma). Measurements of ϵ'_r within this range are sensitive to the RBC shape and aggregation. Moreover, measurements of ϵ'_r at 100 MHz and above are close to the permittivity of water and are thus insensitive to the effects of RBC interfacial polarization. Finally, ϵ''_r is dominated by a combination of the CDL effect and the bulk solution conductivity of blood over the entire frequency range. A detailed analysis of ϵ_r for human whole blood in a microfluidic dielectric sensor and a corresponding circuit model is previously reported in [34]. In this work, we aim to capture the blood coagulation dynamics, including aggregation of RBCs in a fibrin clot and their subsequent shape change as a result of contractile forces from activated platelets. Hence, measurements of Z_S are performed

over the frequency range of 40 Hz to 100 MHz to capture the complete frequency-dependent characteristics of ϵ'_r , including the dispersion region attributed to the RBC interfacial polarization. The time course of variation in ϵ'_r can then be analyzed for blood coagulation monitoring.

B. ClotChip Fabrication and Assembly

Dielectric coagulometry measurements with human whole blood were first performed using a first-generation (Gen-1) ClotChip that was based on a commercially available printed-circuit board (PCB) for the substrate and sensing electrodes, as previously reported in [32], [34]. To minimize the potential for artificial contact activation of the coagulation process, we subsequently manufactured a second-generation (Gen-2) ClotChip that was based on a biocompatible, chemically inert, polymethyl methacrylate (PMMA) plastic substrate and cap [33]. The Gen-2 sensor fabrication and assembly process, as shown in Fig. 2(B), was based on a low-cost (<\$1 material cost per chip) batch-fabrication method of screen-printing gold electrodes onto PMMA plastic material. Screen-printing is a low-temperature fabrication method suitable for biocompatible plastic materials that does not require a cleanroom or advanced microfabrication facilities. A 1.5 mm-thick PMMA substrate was first cleaned using diluted ethyl alcohol. Gold sensing electrodes (3.5 mm \times 1.3 mm with spacing of 0.5 mm) and a floating electrode (4 mm \times 1.5 mm) were screen-printed onto the PMMA material using gold ink (E4464, Ercon Inc, Wareham, MA) and then cured in an oven at 110 °C for 15 minutes. The PMMA material was then laser micromachined (Versa Laser, Scottsdale, AZ) to form the substrate and microfluidic cap. A microfluidic channel with dimensions of 12 mm \times 3 mm was formed by laser micromachining of a double-sided-adhesive (DSA) film and attaching the PMMA cap to the PMMA substrate using the DSA film. The DSA film had a thickness of 250 μ m that defined the microfluidic channel height. The Gen-2 ClotChip had a total sample volume of 9 μ L, which is less than the volume of blood obtained by a finger stick. For all tests, a micropipette was used to inject a sample into the microfluidic channel of the ClotChip through inlet/outlet holes in the PMMA cap. Fig. 2(C) shows a picture of the fabricated sensor prototype loaded with human whole blood as the MUT. As seen in Fig. 2(D), measurements with an impedance analyzer (Agilent 4294A, Santa Clara, CA) were performed using 1m-long 4-terminal extension cables and a custom PCB test fixture that included spring-loaded contact pins to provide a plug-and-play-type connection between the sensor contact pads and measurement equipment. All sensor measurements were corrected for parasitic impedances contributed by the cables and the test fixture via calibration with standard impedances applied to the contact pins.

C. ClotChip Calibration

The ClotChip was calibrated using five reference materials: 20% isopropyl alcohol (IPA) in de-ionized (DI) water, 5% IPA in DI water, 2.5% IPA in DI water, 20% ethanol in DI water, and 10% ethanol in DI water. A commercial dielectric probe kit (Agilent 85070E, Santa Clara, CA) was first used to obtain a

reference permittivity for each material. Next, the Z_S parameter of the sensor loaded with each reference material was measured using the impedance analyzer. A linear least-squares fit between ϵ'_r of the reference materials and Z_S parameter of the sensor loaded with the reference materials was performed based on (2) to find C_0 . The calibration procedure was performed for five frequencies in 14–100 MHz, and C_0 was found to be frequency-independent with a value of 25 fF \pm 0.07 fF for Gen-1 ClotChip and 42.8 fF \pm 0.86 fF for Gen-2 ClotChip. After this one-time calibration was complete, additional sensors were tested without any further calibration, and ϵ'_r of the blood sample in the microfluidic channel was obtained from the sensor impedance measurements using (2).

D. Testing With Human Whole Blood Samples

De-identified, healthy, human whole blood samples were obtained from Research Blood Components, LLC (Brighton, MA) and the Hematopoietic Biorepository and Cellular Therapy Core at Case Western Reserve University under an institutional review board (IRB)-approved protocol. Following the guidelines of the Clinical and Laboratory Standards Institute for blood coagulation testing [35], all blood samples were collected in standard vacutainer tubes containing 3.2% sodium citrate anticoagulant. In some tests, the samples were treated *in vitro* to modulate the coagulation time or platelet activity, as described further in Section III.

E. Assessment of Blood Coagulation Using ClotChip

A heating chamber (Thermotron, Holland, MI) was used to keep the experimental setup at 37 °C. After pipetting 25.6 μ L of 250 mM CaCl₂ in 300 μ L of citrated blood sample, 9 μ L of the mixture was immediately injected into the microfluidic channel of the ClotChip. Excess blood at the inlet/outlet ports was wiped, and the ports were sealed using an adhesive tape to prevent dehydration of the sample. The impedance analyzer was used to measure the Z_S parameter of the sensor over a frequency range of 40 Hz to 100 MHz. These measurements were performed every 30 seconds over 30 minutes.

F. Assessment of Blood Coagulation Using ROTEM

To determine the correlative power of ClotChip to an existing, clinically relevant, whole blood assay of global hemostasis, we carried out studies with the ClotChip and subjected the sample to concurrent ROTEM measurements. In ROTEM measurements, a pin is suspended into a whole blood sample by a torsion wire. The pin rotates within a stationary cup containing the blood sample, and the deflection of the pin is optically measured to determine the viscoelastic properties of blood as it clots [36]. The ROTEM readout is defined as the deflection of the pin (in mm) and can be used to obtain important information on all stages of the coagulation process. The ROTEM clotting time (CT) parameter is the time from the start of the measurement to the initial detection of clot formation as determined when the ROTEM readout reaches an amplitude of 2 mm. The ROTEM maximum clot firmness (MCF) parameter is the maximum amplitude of




Fig. 3. Variation in ϵ'_r of blood during coagulation. (A) Surface plot of the variation in ϵ'_r of human whole blood versus time and frequency. (B) Histogram plot of the peak frequency for all tested blood samples. (C) 2D slice of the surface plot showing variation in ϵ'_r versus time at 1 MHz. (D) 2D slice of the surface plot showing variation in ϵ'_r versus frequency at 5 minutes.

the ROTEM readout, which is a measure of clot stability that is influenced by platelet activity. We therefore chose to compare the ClotChip readout to the ROTEM CT and MCF parameters that provide distinct information on coagulation time and platelet activity, respectively. The ROTEM measurements were performed on a quad-channel computerized device (ROTEM Delta TEM International, Munich, Germany). Citrated whole blood samples were warmed to 37 °C and then 300 μ L of each sample was placed in a disposable cuvette using an electronic pipette. Blood samples were re-calcified with 20 μ L of 0.2 M CaCl_2 prior to the start of the measurement. All pipetting and mixing steps were performed in a standardized way by following an automated electronic pipette program. Each ROTEM measurement lasted 60 minutes and was performed within 2 hours of the time of blood collection, as recommended in [37]. Hence, only two tests were conducted on a given blood sample for all ROTEM measurements.

G. Statistical Analysis

The data obtained in this study are reported as mean \pm standard deviation unless stated otherwise. The data were analyzed using analysis of variance (ANOVA) with Tukey's post hoc test for multiple comparisons, with the statistical significance threshold set at 95% confidence level for all tests ($p < 0.05$). Statistical analyses were performed with Minitab 17 (Minitab, State College, PA) and GraphPad Prism (GraphPad Software, La Jolla,

CA) software suites. Pearson's correlation was used to obtain correlative statistics between the ClotChip readout parameters and ROTEM parameters.

III. MEASUREMENT RESULTS AND DISCUSSION

A. Variation in ϵ'_r of Human Whole Blood Versus Time and Frequency During Coagulation

The surface plot in Fig. 3(A) shows the variation in ϵ'_r over time and frequency for human whole blood (supplemented with sodium citrate as anticoagulant) upon addition of CaCl_2 to initiate coagulation. The readouts were obtained by the Gen-1 ClotChip and normalized to the permittivity values at the start of the experiment (i.e., $t = 0$). An increase in the normalized permittivity was observed in the dispersion region (~ 500 kHz to 50 MHz), with the maximum rise occurring around 1 MHz followed by a fall in permittivity values. The frequency point at which the normalized permittivity exhibited the highest value was obtained for all the CaCl_2 -treated blood samples, and is referred to as the peak frequency herein.

A histogram of all the peak frequency values is plotted in Fig. 3(B), demonstrating that the majority of the blood samples exhibited a peak frequency around 1 MHz. Subsequently, the frequency point of 1 MHz was selected to capture the temporal variation in normalized permittivity of a given blood sample in order to provide an estimate of its coagulation time. Fig. 3(C) depicts a 2D slice of the surface plot, showing the




Fig. 4. Time course of variation in ϵ'_r at 1 MHz for human whole blood without (black square) and with (blue diamond) coagulation initiated by the addition of CaCl_2 to a citrated (anticoagulated) blood sample [32].

temporal variation in normalized permittivity at 1 MHz, whereas Fig. 3(D) depicts another slice of the surface plot, showing variation in normalized permittivity versus frequency at $t = 5$ minutes.

Fig. 4 shows the temporal variation in ϵ'_r at 1 MHz for another CaCl_2 -treated human whole blood sample undergoing coagulation in the ClotChip. Similar to Fig. 3(C), the plot (blue diamond) revealed a permittivity peak at around $t = 4.5$ minutes, referred to as T_{peak} herein, which was taken to be indicative of the coagulation time. The coagulation time was also independently assessed visually by periodically dipping a micropipette tip every two minutes in a polypropylene tube containing the same blood sample, and was observed to be around 6 minutes [32]. The same blood sample was also tested in the ClotChip *without* re-calcification, as a control measurement in which blood coagulation did not occur. The second plot (black square) in Fig. 4 shows the temporal variation in ϵ'_r for the anticoagulated blood sample without CaCl_2 treatment (i.e., control). No permittivity peak was observed in the control blood sample. Furthermore, visual observation of the sample also revealed no clot formation even after an hour of monitoring. Collectively, these results showed that the ClotChip T_{peak} parameter was a plausible surrogate for the coagulation time.

B. Variation in Coagulation Time With Temperature

Earlier studies have shown that temperature variation causes a change in the blood coagulation time [38]. In this study, the ambient temperature was changed and its effect on the coagulation time of a CaCl_2 -treated whole blood sample (supplemented with sodium citrate as anticoagulant) was investigated. Following temperature equilibration and addition of 250 mM CaCl_2 , the blood sample was injected into the ClotChip, and the temporal variation in its ϵ'_r was recorded for 30 minutes at four different temperatures of 25 °C, 31 °C, 37 °C, and 43 °C, as shown in Fig. 5(A). The experiments were repeated using the same blood sample in a polypropylene tube kept at the same temperature for visual observation of the coagulation time. Fig. 5(B) shows the mean coagulation times of human whole blood at each temperature obtained with the ClotChip as well as with visual observation of the sample. The Tukey's HSD test was performed, which indicated a statistically significant change

in coagulation time versus temperature for both the ClotChip and visual observation-based procedure. Interestingly, the test also indicated that the ClotChip was capable of detecting a statistically significant change in the coagulation time between 31 °C and 43 °C, which was not detectable by visual observation alone. Fig. 5(C) shows a plot of the ClotChip readout of the coagulation time (i.e., T_{peak}) versus temperature, illustrating a power relationship between the two parameters. Such a relationship has also been previously shown using standard laboratory assays (PT) to measure the effect of temperature on the plasma coagulation time [39]. Furthermore, these findings were also in agreement with previous reports, which stated that decreasing the temperature results in reduction of enzyme activity and platelet function as well as dysregulation of clotting factors, thereby prolonging the blood coagulation time [40]. The absence of statistically significant change in the coagulation time between 31 °C and 37 °C in Fig. 5(B) was also in agreement with previous reports, which stated that both platelet function and enzyme activity are only slightly reduced in the mild hypothermic range (~ 33 °C to 37 °C) and vary significantly only when the temperature is much lower than that [41]–[43].

C. Variation in Coagulation Time With CaCl_2 Concentration

Earlier studies have also reported that the presence of free Ca^{2+} ions is necessary for the blood coagulation process to initiate [44]. As stated previously, to prevent immediate commencement of this process, whole blood was collected in tubes coated with 3.2% sodium citrate anticoagulant, where the citrate acted as a chelating agent by binding with the calcium present in the blood (ratio of blood to anticoagulant = 9:1). To mimic blood coagulation *in vitro*, CaCl_2 was then added to the citrated blood so that there would be an excess of Ca^{2+} ions to initiate blood coagulation [45]. The effect of varying the CaCl_2 concentration on the coagulation time was further investigated in this study.

Following temperature equilibration at 37 °C, the citrated blood sample was treated with CaCl_2 solution at 30 mM, 40 mM, 50 mM, and 250 mM concentrations, and the temporal variation in ϵ'_r was subsequently recorded for 30 minutes by the ClotChip. The experiments were repeated using the same blood sample in a polypropylene tube and at the same CaCl_2 concentration for visual observation of the coagulation time. Fig. 6(A) shows the mean coagulation times of human whole blood at each CaCl_2 concentration obtained with the ClotChip as well as with visual observation of the sample. Similar to the temperature studies, the Tukey's HSD test indicated a statistically significant change in coagulation time versus CaCl_2 concentration for both the ClotChip and visual observation-based procedure. In fact, these measurements revealed that the ClotChip was capable of detecting a statistically significant change in the coagulation time between CaCl_2 concentrations of 30 mM and 40 mM, in contrast to visual observation alone. Fig. 6(B) depicts a plot of the ClotChip readout of the coagulation time (i.e., T_{peak}) versus CaCl_2 concentration, illustrating a power relationship between the two parameters. Such a relationship has been previously reported between the coagulation time of citrated human plasma and concentration of free Ca^{2+} ions added to plasma [46].




Fig. 5. Variation in coagulation time induced by a change in temperature. (A) Time course of variation in ϵ_r' at 1 MHz for CaCl_2 -treated human whole blood at various temperatures. (B) Bar graph comparing the ClotChip readout parameter T_{peak} versus visual observation-based readings of the coagulation time for various temperatures. Horizontal lines indicate statistically significant difference in coagulation time at different temperatures ($p < 0.05$). (C) Fitted curve to the ClotChip readout parameter T_{peak} showing a power relationship between the coagulation time and temperature ($R^2 = 0.8876$). Error bars represent the standard deviation of measurements run in triplicate for each temperature.




Fig. 6. Variation in coagulation time induced by changes in CaCl_2 concentration. (A) Bar graph comparing the ClotChip readout parameter T_{peak} versus visual observation-based readings of the coagulation time for various CaCl_2 concentrations. Horizontal lines indicate statistically significant difference in coagulation time at different concentrations ($p < 0.05$). (B) Fitted curve to the ClotChip readout parameter T_{peak} showing a power relationship between the coagulation time and CaCl_2 concentration ($R^2 = 0.8344$). Error bars represent the standard deviation of measurements run in triplicate for each CaCl_2 concentration.

With lower CaCl_2 concentrations of 10 mM and 20 mM, no coagulation was observed even after 30 minutes of visual observation. At such low concentrations of CaCl_2 , a relatively small

number of free Ca^{2+} ions were added into the citrated whole blood sample, and hence the coagulation was very weak and not observable. As the CaCl_2 concentration was increased beyond 30 mM, the coagulation time rapidly decreased until it reached a value of around 5 minutes at a concentration of 50 mM. Increasing the CaCl_2 concentration beyond this point had little effect on the coagulation time.

D. ClotChip Response to Coagulation Defects via Thrombin Inhibition and Comparison to ROTEM CT Parameter

Human whole blood samples from three healthy volunteers were subjected to *in vitro* treatment for modulating the ClotChip T_{peak} and ROTEM CT parameters. Argatroban is a direct thrombin inhibitor that can function as an antithrombotic agent even in the absence of any other cofactors. Its selective inhibitory mechanism enables Argatroban to block both circulating and clot-bound thrombin, thereby increasing the coagulation time [47]. On the other hand, thrombin is a strong pro-coagulant agent that accelerates clot formation. Thrombin has multiple functions in the blood coagulation process, including activation of platelets through their thrombin receptors, enhancing the conversion of fibrinogen into fibrin, and activation of factors V, VIII, XI, and XIII [48], [49]. Each blood sample was therefore tested as untreated, treated with Argatroban (Sellcheck, Houston, TX) with a final Argatroban concentration of 5 μM or 10 μM , or treated with human gamma thrombin (Enzyme Research Laboratories, South Bend, IN) with a final thrombin concentration of 150 pM or 300 pM. Blood samples treated with Argatroban were incubated for an additional 15 minutes at 37 °C before adding CaCl_2 , whereas no such additional incubation time was used with the thrombin-treated samples.

The Gen-2 ClotChip was utilized for these studies in which the T_{peak} parameter of the ClotChip readout was compared against the ROTEM CT parameter. Fig. 7(A) shows the temporal variation in ϵ_r' at 1 MHz for an untreated, anti-thrombin-treated (final Argatroban concentration of 10 μM), and thrombin-




Fig. 7. Comparison of ClotChip T_{peak} and ROTEM CT parameters. (A) Time course of variation in ϵ'_r at 1 MHz for an untreated whole blood sample and for the same sample treated with anti-thrombin as well as thrombin. (B) ROTEM profiles obtained for the three blood samples used in (A). The arrow shows the clotting time (CT) of the anti-thrombin-treated blood sample, defined as the time taken for the ROTEM profile to reach an amplitude of 2 mm. (C) A very strong positive correlation ($r = 0.99$, $p < 0.0001$, $n = 9$) was observed between the ClotChip T_{peak} and ROTEM CT parameters. For all plots, error bars indicate duplicate measurements and are presented as mean \pm standard error of the mean (SEM).

treated (final thrombin concentration of 150 pM) human whole blood sample from one of the healthy volunteers. As compared to the untreated sample, for which the ClotChip T_{peak} parameter was found to be $330 \text{ s} \pm 30 \text{ s}$, the ClotChip readout exhibited a prolonged T_{peak} of $1,440 \text{ s} \pm 120 \text{ s}$ for the anti-thrombin-treated sample. On the other hand, T_{peak} was shortened to $45 \text{ s} \pm 15 \text{ s}$ for the thrombin-treated sample.

Fig. 7(B) shows the corresponding ROTEM readouts for the same three blood samples in Fig. 7(A) that are overlaid on top of each other. The ROTEM CT parameter for the untreated sample was recorded as $346 \text{ s} \pm 22 \text{ s}$. Similar to the ClotChip results, the ROTEM recorded the longest CT ($1,328 \text{ s} \pm 163 \text{ s}$) for the anti-thrombin-treated sample and the shortest CT ($75 \text{ s} \pm 5 \text{ s}$) for the thrombin-treated sample.

Next, results from all nine untreated, anti-thrombin-treated, and thrombin-treated whole blood samples were used to assess the correlative power of the ClotChip T_{peak} parameter to the ROTEM CT parameter. As shown in Fig. 7(C), T_{peak} exhibited a very strong positive correlation ($r = 0.99$, $p < 0.0001$) to the ROTEM CT parameter. The latter is a clinically important indicator of a patient's coagulation status and is prolonged in patients with clotting factor deficiencies or on anticoagulant therapy. Hence, the strong correlation between T_{peak} and CT parameters shows the ClotChip potential to provide clinically important information on a patient's coagulation status.

E. ClotChip Response to Platelet Activity Inhibition and Comparison to ROTEM MCF Parameter

To investigate the effect of platelet activity inhibition on the ClotChip measurements, human whole blood samples from four healthy volunteers were subjected to *in vitro* treatment with cytochalasin D (CyD) with various final concentrations in the range of $0 \mu\text{M}$ (i.e., untreated) to $10 \mu\text{M}$. CyD is a potent inhibitor of actin polymerization and hence inhibits platelet activation and hemostatic function [50], [51]. Blood samples from three volunteers were treated with three different CyD concentrations, whereas the sample from the remaining volunteer was treated with four different CyD concentrations, resulting in a total of 13 blood samples. All samples were re-calcified with CaCl_2 prior to measurements with the Gen-2 ClotChip and ROTEM.

Fig. 8(A) shows the temporal variation in ϵ'_r at 1 MHz for three samples with final CyD concentrations of $0 \mu\text{M}$, $2.5 \mu\text{M}$, and $10 \mu\text{M}$. As can be seen, for increased concentrations of CyD (i.e., an increased effect of platelet activity inhibition), the ClotChip readout exhibited a decreased $\Delta\epsilon_{r,max}$ parameter, which was defined as one minus the ratio of final permittivity (i.e., permittivity at 30 minutes) and peak permittivity (i.e., permittivity at T_{peak}). This showed that the ClotChip $\Delta\epsilon_{r,max}$ parameter was sensitive at measuring platelet function.

Fig. 8(B) shows the corresponding ROTEM readouts for the same three blood samples in Fig. 8(A) that are overlaid on top of each other. The addition of CyD significantly reduced the ROTEM MCF parameter, with blood samples with higher CyD concentrations recording lower MCF values. Finally, all thirteen whole blood samples were used to assess the correlative power of the ClotChip $\Delta\epsilon_{r,max}$ parameter to the ROTEM MCF parameter. As shown in Fig. 8(C), $\Delta\epsilon_{r,max}$ exhibited a strong positive correlation ($r = 0.85$, $p < 0.001$) to the ROTEM MCF parameter.

The results of all these experiments establish that the ClotChip readout is sensitive to multiple components of the hemostatic process and can provide a discriminatory readout of coagulation time and platelet activity through two independent readout parameters. Furthermore, strong positive correlation of the ClotChip readout parameters to those of ROTEM demonstrates that monitoring the time course of variation in blood dielectric permittivity at 1 MHz during the coagulation process has the potential to provide clinically important information on the complete hemostatic process from a single drop of whole blood on a single disposable sensor. Unlike ROTEM, the ClotChip




Fig. 8. Comparison of ClotChip $\Delta\epsilon_{r,max}$ and ROTEM MCF parameters. (A) Time course of variation in ϵ'_r at 1 MHz for an untreated whole blood sample (CyD concentration of 0 μM) and for the same sample treated with CyD concentrations of 2.5 μM and 10 μM . (B) ROTEM profiles obtained for the three blood samples used in (A). The arrows show the maximum clot firmness (MCF) of the 10 μM -CyD-treated blood sample. (C) A strong positive correlation ($r = 0.85$, $p < 0.001$, $n = 13$) was observed between the ClotChip $\Delta\epsilon_{r,max}$ and ROTEM MCF parameters. For all plots, error bars indicate duplicate measurements and are presented as mean \pm SEM.

does not require sensitive mechanical components to interact with the blood sample. Leveraging the fully electrical technique of DS, the ClotChip can ultimately be developed into a small-sized, handheld platform for POC assessment of hemostasis.

IV. CONCLUSION

This paper reported on the design, fabrication, and testing of a low-cost, microfluidic, capacitive sensor, termed ClotChip, for the analysis of blood coagulation process. The sensor was shown to measure the real part of the complex relative dielectric permittivity of human whole blood in a frequency range of 40 Hz to 100 MHz, and to provide a readout of the blood coagulation process from the temporal variation in dielectric permittivity at 1 MHz using $< 10 \mu\text{L}$ of blood sample volume. Two independent parameters of the ClotChip readout, T_{peak} and $\Delta\epsilon_{r,max}$, were shown to provide distinct information related to the coagulation time and platelet activity, respectively. Further evaluation of the ClotChip readout and its comparison to the clinically important

ROTEM assay revealed a very strong positive correlation ($r = 0.99$, $p < 0.0001$) between the ClotChip T_{peak} and the ROTEM CT parameters, and a strong positive correlation ($r = 0.85$, $p < 0.001$) between the ClotChip $\Delta\epsilon_{r,max}$ and the ROTEM MCF parameters. The ClotChip holds potential to be a truly low-cost, small-sized, disposable microfluidic sensor that enables rapid and comprehensive diagnosis of blood coagulation and platelet defects at the POC. Our future work will focus on the clinical evaluation of the ClotChip with blood samples from patients with coagulation and platelet defects, as well as patients on antiplatelet/anticoagulant therapies.

ACKNOWLEDGMENT

The authors would like to thank G. Gongaware, MIM Software, Beachwood, OH, USA for illustrating Fig. 1. The contents of this manuscript do not represent the views of the United States Department of Veterans Affairs or the United States Government. *Conflict of Interests Disclosure:* D. Maji, M. A. Suster, U. A. Gurkan, E. X. Stavrou, and P. Mohseni are inventors of intellectual property related to the ClotChip that is licensed by Case Western Reserve University to XaTek, Inc., Cleveland, OH, USA.


REFERENCES

- [1] E. Gonzalez *et al.*, "Trauma-induced coagulopathy: An institution's 35 year perspective on practice and research," *Scand. J. Surg.*, vol. 103, no. 2, pp. 89–103, Jun. 2014.
- [2] L. Harris, V. Castro-López, and A. Killard, "Coagulation monitoring devices: Past, present, and future at the point-of-care," *TrAC Trends Analytical Chem.*, vol. 50, pp. 85–95, 2013.
- [3] H. Schöchl *et al.*, "Goal-directed coagulation management of major trauma patients using thromboelastometry (ROTEM)-guided administration of fibrinogen concentrate and prothrombin complex concentrate," *Crit. Care*, vol. 14, no. 2, pp. 1–11, 2010, Art. no. R55.
- [4] B. Eastridge *et al.*, "Death on the battlefield (2001–2011)," *J. Trauma Acute Care Surg.*, vol. 73, pp. S431–S437, 2012.
- [5] L. T. da Luz, B. Nascimento, and S. Rizoli, "Thromboelastography (TEG): Practical considerations on its clinical use in trauma resuscitation," *Scand. J. Trauma, Resuscitation Emergency Med.*, vol. 21, no. 1, pp. 1–8, 2013.
- [6] B. S. Karon, "Why is everyone so excited about thromboelastography (TEG)?" *Clin. Chim. Acta*, vol. 436, pp. 143–148, Sep. 2014.
- [7] L. G. Puckett *et al.*, "Magnetoelastic transducers for monitoring coagulation, clot inhibition, and fibrinolysis," *Biosensors Bioelectron.*, vol. 20, no. 9, pp. 1737–1743, Mar. 2005.
- [8] L. Müller *et al.*, "Investigation of prothrombin time in human whole-blood samples with a quartz crystal biosensor," *Anal. Chem.*, vol. 82, no. 2, pp. 658–663, Jan. 2010.
- [9] W. Xu, J. Appel, and J. Chae, "Real-time monitoring of whole blood coagulation using a microfabricated contour-mode film bulk acoustic resonator," *J. Microelectromech. Syst.*, vol. 21, no. 2, pp. 302–307, Apr. 2012.
- [10] V. Djakov, E. Huq, and P. Vernon, "Fluid probe," Patent US8607619 B2, Dec. 17, 2013.
- [11] O. Cakmak *et al.*, "A cartridge-based sensor array platform for multiple coagulation measurements from plasma," *Lab Chip*, vol. 15, no. 1, pp. 113–120, 2015.
- [12] R. M. Judith *et al.*, "Micro-elastometry on whole blood clots using actuated surface-attached posts (ASAPs)," *Lab Chip*, vol. 15, no. 5, pp. 1385–1393, 2015.
- [13] X. M. Liang *et al.*, "Platelet retraction force measurements using flexible post force sensors," *Lab Chip*, vol. 10, no. 8, pp. 991–998, 2010.
- [14] F. Viola *et al.*, "A novel ultrasound-based method to evaluate hemostatic function of whole blood," *Clin. Chim. Acta*, vol. 411, no. 1/2, pp. 106–113, Jan. 2010.
- [15] M. M. Tripathi, Z. Hajjarian, E. M. Van Cott, and S. K. Nadkarni, "Assessing blood coagulation status with laser speckle rheology," *Biomed. Opt. Express*, vol. 5, no. 3, pp. 817–831, Mar. 2014.

- [16] U. Kaatz and Y. Feldman, "Broadband dielectric spectrometry of liquids and biosystems," *Meas. Sci. Technol.*, vol. 17, pp. R17–R35, 2006.
- [17] F. Kremer, "Dielectric spectroscopy—Yesterday, today and tomorrow," *J. Non-Cryst. Solids*, vol. 305, no. 1–3, pp. 1–9, Jul. 2002.
- [18] S. Abdalla, S. S. Al-Ameer, and S. H. Al-Maghaishi, "Electrical properties with relaxation through human blood," *Biomicrofluidics*, vol. 4, pp. 1–16, 2010, Art. no. 034101.
- [19] M. Wolf, R. Gulich, P. Lunkenheimer, and A. Loidl, "Broadband dielectric spectroscopy on human blood," *Biochim. Biophys. Acta*, vol. 1810, no. 8, pp. 727–740, Aug. 2011.
- [20] K. Asami, "Characterization of biological cells by dielectric spectroscopy," *J. Non-Cryst. Solids*, vol. 305, no. 1–3, pp. 268–277, Jul. 2002.
- [21] K. Heileman, J. Daoud, and M. Tabrizian, "Dielectric spectroscopy as a viable biosensing tool for cell and tissue characterization and analysis," *Biosensors Bioelectron.*, vol. 49, pp. 348–359, Nov. 2013.
- [22] K. Asami and K. Sekine, "Dielectric modeling of erythrocyte aggregation in blood," *J. Phys. D, Appl. Phys.*, vol. 40, no. 7, pp. 2197–2204, 2007.
- [23] Y. Hayashi *et al.*, "Dielectric inspection of erythrocyte morphology," *Phys. Med. Biol.*, vol. 53, no. 10, pp. 2553–2564, 2008.
- [24] C. Merla *et al.*, "Dielectric spectroscopy of blood cells suspensions: Study on geometrical structure of biological cells," in *Proc. Int. IEEE Eng. Med. Biol. Conf.*, Aug. 2006, pp. 3194–3197.
- [25] J. R. Byrnes *et al.*, "Factor XIIIa-dependent retention of red blood cells in clots is mediated by fibrin α -chain crosslinking," *Blood*, vol. 126, no. 16, pp. 1940–1948, Oct. 2015.
- [26] A. Ur, "Determination of blood coagulation using impedance measurements," *Biomed. Eng.*, vol. 5, no. 7, pp. 342–345, Jul. 1970.
- [27] A. Ur, "Detection of clot retraction through changes of the electrical impedance of blood during coagulation," *Amer. J. Clin. Pathol.*, vol. 56, no. 6, pp. 713–718, Dec. 1971.
- [28] A. Ur, "Changes in the electrical impedance of blood during coagulation," *Nature*, vol. 226, no. 5242, pp. 269–270, Apr. 1970.
- [29] Y. Hayashi *et al.*, "Dielectric coagulometry: A new approach to estimate venous thrombosis risk," *Anal. Chem.*, vol. 82, no. 23, pp. 9769–9774, Dec. 2010.
- [30] S. Chiba *et al.*, "Dielectric blood coagulometry as a novel coagulation test," *J. Sci. Res. Rep.*, vol. 4, no. 3, pp. 180–188, Jan. 2015.
- [31] Y. Hayashi, M. A. Brun, K. Machida, and M. Nagasawa, "Principles of dielectric blood coagulometry as a comprehensive coagulation test," *Anal. Chem.*, vol. 87, no. 19, pp. 10072–10079, Oct. 2015.
- [32] D. Maji *et al.*, "Monitoring time course of human whole blood coagulation using a microfluidic dielectric sensor with a 3D capacitive structure," in *Proc. Int. IEEE Eng. Med. Biol. Conf.*, Aug. 2015, pp. 5904–5907.
- [33] D. Maji *et al.*, "A PMMA microfluidic dielectric sensor for blood coagulation monitoring at the point-of-care," in *Proc. Int. IEEE Eng. Med. Biol. Conf.*, Aug. 2016, pp. 291–294.
- [34] M. A. Suster, N. H. Vitale, D. Maji, and P. Mohseni, "A circuit model of human whole blood in a microfluidic dielectric sensor," *IEEE Trans. Circuits Syst. II, Express Briefs*, vol. 63, no. 12, pp. 1156–1160, Dec. 2016.
- [35] D. M. Adcock *et al.*, "Collection, Transport and Processing of Blood Specimens for Testing Plasma-Based Coagulation Assays and Molecular Hemostasis Assays: Approved Guideline (CLSI Document H21-A5), 5th ed. Wayne, PA, USA: Clin. Lab. Stand. Inst., 2008, vol. 28, pp. 1–33.
- [36] D. Bolliger, M. D. Seeberger, and K. A. Tanaka, "Principles and practice of thromboelastography in clinical coagulation management and transfusion practice," *Transfusion Med. Rev.*, vol. 26, no. 1, pp. 1–13, 2012.
- [37] M. Chitlur *et al.*, "Recommendations for performing thromboelastography/thromboelastometry in hemophilia: Communication from the SSC of the ISTH," *J. Thrombosis Haemostasis*, vol. 12, no. 1, pp. 103–106, 2014.
- [38] A. S. Wolberg, Z. H. Meng, D. M. I. Monroe, and M. Hoffman, "A systematic evaluation of the effect of temperature on coagulation enzyme activity and platelet function," *J. Trauma Acute Care Surg.*, vol. 56, no. 6, pp. 1221–1228, Jun. 2004.
- [39] G. R. Minot, "The effect of temperature upon the clotting time (prothrombin time) of oxalated plasma with calcium," *J. Medical Research*, vol. 33, no. 3, pp. 503–506, Jan. 1916.
- [40] A. W. Kirkpatrick, R. Chun, R. Brown, and R. K. Simons, "Hypothermia and the trauma patient," *Can. J. Surg.*, vol. 42, no. 5, pp. 333–343, 1999.
- [41] R. L. Reed *et al.*, "Hypothermia and blood coagulation: dissociation between enzyme activity and clotting factor levels," *Circ. Shock*, vol. 32, no. 2, pp. 141–152, Oct. 1990.
- [42] R. L. Reed, T. D. Johnston, J. D. Hudson, and R. P. Fischer, "The disparity between hypothermic coagulopathy and clotting studies," *J. Trauma Acute Care Surg.*, vol. 33, no. 3, pp. 465–470, Sep. 1992.
- [43] K. D. Gubler, L. M. Gentilello, S. A. Hassantash, and R. V. Maier, "The impact of hypothermia on dilutional coagulopathy," *J. Trauma*, vol. 36, no. 6, pp. 847–851, 1994.
- [44] J. Mellanby, "The coagulation of blood," *J. Physiol.*, vol. 38, no. 1, pp. 28–112, Dec. 1908.
- [45] M. Dawson and G. R. Milne, "The collection and storage of blood," in *Immunological and Blood Products*. Oxford, U.K.: Butterworth-Heinemann, 1967, pp. 133–148.
- [46] F. I. Ataulakhanov, A. V. Pohilko, E. I. Sinauridze, and R. I. Volkova, "Calcium threshold in human plasma clotting kinetics," *Thrombosis Res.*, vol. 75, no. 4, pp. 383–394, Aug. 1994.
- [47] G. Escolar, J. Bozzo, and S. Maragall, "Argatroban: A direct thrombin inhibitor with reliable and predictable anticoagulant actions," *Drugs Today*, vol. 42, no. 4, pp. 223–236, 2006.
- [48] J. T. B. Crawley *et al.*, "The central role of thrombin in hemostasis," *J. Thrombosis Haemostasis*, vol. 5, pp. 95–101, Jul. 2007.
- [49] S. Narayanan, "Multifunctional roles of thrombin," *Ann. Clin. Lab. Sci.*, vol. 29, no. 4, pp. 275–280, Oct. 1999.
- [50] O. E. Olorundare, S. R. Simmons, and R. M. Albrecht, "Cytochalasin D and E: Effects on fibrinogen receptor movement and cytoskeletal reorganization in fully spread, surface-activated platelets: A correlative light and electron microscopic investigation," *Blood*, vol. 79, no. 1, pp. 99–109, 1992.
- [51] T. Lang *et al.*, "Different effects of abciximab and cytochalasin D on clot strength in thromboelastography," *J. Thrombosis Haemostasis*, vol. 2, no. 1, pp. 147–153, 2004.



Debnath Maji (S'15) was born in 1990. He received the B.Tech. and M.Tech. dual degrees in electronics and electrical communication engineering from the Indian Institute of Technology, Kharagpur, Kharagpur, India, in 2013, developing a CMOS microthermal accelerometer with high linearity and sensitivity. Since 2014, he has been working toward the Ph.D. degree at Case Western Reserve University, Cleveland, OH, USA. His research interest focuses on sensor design at the interface of electrical, mechanical, and biomedical engineering. His research is currently focused on developing an autonomous, small-sized, low-power, and portable sensor system for rapid, high-throughput, and low-cost dielectric spectroscopy measurements with biological fluids.



Michael A. Suster (S'06–M'11) was born in 1978. He received the B.S., M.S., and Ph.D. degrees in electrical engineering from Case Western Reserve University, Cleveland, OH, USA, in 2002, 2006, and 2011, respectively. He was a Postdoctoral Researcher in the Department of Electrical and Computer Engineering, University of Utah, Salt Lake City, UT, USA. He is currently a Senior Research Associate in the Department of Electrical Engineering and Computer Science, Case Western Reserve University. His research interests include analog/mixed-signal/RF integrated circuits for micro/nano-sensors, and CMOS biosensors. He has authored numerous papers in refereed IEEE journals and international conferences and has served as a Technical Reviewer for various IEEE publications. He is a member of the IEEE as well as the IEEE Solid-State Circuits Society.



Erdem Kucukal received the B.S. degree in mechanical engineering from Kocaeli University, Kocaeli, Turkey, in 2010, and the M.S. degree in mechanical engineering from Case Western Reserve University, Cleveland, OH, USA, in 2015. Since 2015, he has been working toward the Ph.D. degree at the CASE Biomanufacturing and Microfabrication Laboratory, Department of Mechanical & Aerospace Engineering, Case Western Reserve University. He was involved in several different projects mainly focused on computational and experimental methods in fluid mechanics and heat transfer during his undergraduate and graduate work. He was supported through a prestigious scholarship program provided by the Turkish Ministry of National Education during his M.S. studies. His research interests include design and integration of microfluidic systems for probing adhesion mechanics of different cell types in biomimicking environments. He is motivated and driven to conduct multidisciplinary engineering research where his vision is to bridge engineering, science, and medicine. He has been a member of the American Society of Mechanical Engineers since 2015.



Ujjal D. S. Sekhon received the B.E. degree in biotechnology engineering from Panjab University, Chandigarh, India, in 2014 and is currently working toward the Ph.D. degree in biomedical engineering in the laboratory of Prof. Anirban Sen Gupta in the Department of Biomedical Engineering, Case Western Reserve University, Cleveland, OH, USA. His current research interests include the development and evaluation of enzyme-responsive polymeric biomaterials and technologies for hemostasis, wound healing, and drug-delivery applications.



Anirban Sen Gupta received the B.Sc. degree (Hons.) in chemistry in 1995 and the B.Tech. degree in chemical engineering in 1998 from the University of Calcutta, Kolkata, India, and the M.S. and Ph.D. degrees in chemical engineering from the University of Akron, Akron, OH, USA, in 2003. He is an Associate Professor of biomedical engineering at Case Western Reserve University, Cleveland, OH, USA, and the Director of Bio-Inspired Engineering for Advanced Technologies Laboratory. His expertise is in the area of polymeric biomaterials, blood-

biomaterial interactions, coagulation dysfunctions, targeted drug delivery, and nanomedicine. His laboratory's current research is in hemostatic biomaterials and technologies, targeted drug delivery in cardiovascular and cancer pathologies, and enzyme-responsive polymers for hemostasis and wound healing applications.



Umut A. Gurkan (M'13) received the B.S. degrees in chemical engineering and mechanical engineering from the Middle East Technical University, Ankara, Turkey, and the Ph.D. degree in biomedical engineering from Purdue University, West Lafayette, IN, USA. He completed his postdoctoral training in medicine at Brigham and Women's Hospital (Harvard Medical School) and Harvard-MIT Health Sciences and Technology after which he joined the Case Western Reserve University as an Assistant Professor of mechanical and aerospace engineering. He is leading

the CASE Biomanufacturing and Microfabrication Laboratory whose mission is to improve human health and quality of life through a fundamental understanding of cell biomechanics, and through innovations in micro-/nano-engineering, microfluidics, biosensors, and point-of-care systems. He has received national and international recognitions and awards for research and education, including the NSF CAREER Award, "Rising Star" Award from the Biomedical Engineering Society (Cellular and Molecular Bioengineering and Advanced Biomanufacturing Divisions), MIT Technology Review Innovator Under 35 Award (Turkey), Case-Coulter Translational Research Partnership Award, Clinical and Translational Science Collaborative Award, Case School of Engineering Research Award, Doris Duke Innovations in Clinical Research Award, Belcher-Weir Family Pediatric Innovation Award, Translational Research Featured New Investigator Award from the Central Society for Clinical and Translational Research, and Glennan Fellowship from the University Center for Innovation in Teaching and Education. He has authored more than 55 research and review articles in leading peer-reviewed journals, in addition to numerous book chapters and patents. Three of his patents have been licensed for commercialization. He is a member of the American Society of Hematology, American Society of Mechanical Engineers, IEEE Engineering in Medicine and Biology Society, and Biomedical Engineering Society.



Evi X. Stavrou received the M.D. degree (*summa cum laude*) from Semmelweis University, Budapest, Hungary. She is the Oscar D. Ratnoff Professor of medicine and hematology at the Case Western Reserve University, Cleveland, OH, USA, and the Staff Hematologist at the Louis Stokes Cleveland VA Medical Center, Cleveland, OH, USA. She performed her internal medicine training at the Johns Hopkins University-Sinai Program, Baltimore, MD, USA, and subsequently completed her hematology-oncology training at the University Hospitals Case Medical

Center, Cleveland, OH, USA. Her current research interest focuses on nonenzymatic functions of coagulation factor XII as they relate to thromboinflammation. Her work has been published in premier journals including *Blood*, *the Journal of Thrombosis and Haemostasis*, and *Nature Communications*. She has been a speaker in many national and international conferences including the American Society of Hematology and the International Society on Haemostasis and Thrombosis (ISTH). In 2014, she was appointed the Co-Chair of the Scientific Subcommittee on Factor XI and the Contact System of ISTH. She is an Associate Editor of the *Frontiers in Hematology* and is a member of Thrombosis Research Publications Committee. She has ongoing collaborations with the Departments of Electrical and Biomedical Engineering, developing novel microfluidic platforms for real-time study of coagulation. She is also an investigator at the Advanced Platform Technology (APT) Center of the Louis Stokes Cleveland VA Medical Center. Her work is funded by the American Heart Association, VA Research & Education Foundation, APT Center, and previously from the Haemostasis and Thrombosis Research Society.



Pedram Mohseni (S'94-M'05-SM'11) received the B.S. degree from the Sharif University of Technology, Tehran, Iran, in 1996, and the M.S. and Ph.D. degrees from the University of Michigan, Ann Arbor, MI, USA, all in electrical engineering, in 1999 and 2005, respectively. He is currently a Tenured Full Professor in the Department of Electrical Engineering and Computer Science, Case Western Reserve University, Cleveland, OH, USA, with a secondary appointment in the Department of Biomedical Engineering. His research interests include analog/mixed-

signal/RF integrated circuits and microsystems for neural engineering, wireless sensing/actuating systems for brain-machine interfaces, interface circuits for micro-/nano-scale sensors/actuators, and point-of-care diagnostic platforms for personalized healthcare. He has been an Associate Editor of several IEEE journals since 2008, as well as a member of the Technical Program Committee of the IEEE RFIC Symposium (2012–2015), CICC (2012–present), and ISSCC (2017). He is the author of two book chapters, five issued and pending patents, and more than 90 refereed technical and scientific articles. He has received several awards including the National Science Foundation CAREER Award in 2009, Case School of Engineering Research Award in 2011, first-place prize of the Medical Device Entrepreneur's Forum at the 58th Annual Conference of the ASAIO in 2012, and EECS Mihajlo "Mike" Mesarovic Award for Extraordinary Impact in 2013. He is a member of the IEEE SOLID-STATE CIRCUITS, CIRCUITS AND SYSTEMS, and Engineering in Medicine and Biology Societies, as well as the administrative committee of the IEEE Sensors Council (2014–present). He is the General Co-Chair of the 2018 IEEE Biomedical Circuits and Systems Conference, Cleveland, OH, USA.